All In Biotech

Drug Trial Radar · NCT06232096

A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

A Phase Ⅰ/Ⅱ Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of MBS314 Injection in Patients With Relapsed/Refractory Multiple Myeloma.

Last checked: Nov 19, 2026Latest source record: Mar 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

154

Planned (sponsor's estimate)

Start

Feb 22, 2024

Primary completion

Feb 2026

Study completion Mar 2028

Sponsor

Sponsor type
Industry
First posted
Jan 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel asymmetric trivalent tri-specific humanized antibody, MBS314, administered by intravenous (IV) infusion in participants with relapsed or refractory multiple myeloma. This entry-to-human study is divided in 2 parts: a dose escalation part (Phase Ⅰa) and an expansion part (Phase Ⅰb/Ⅱ).

Conditions

  • Relapsed or Refractory Multiple Myeloma

Interventions

  • MBS314 InjectionDrug

    Phase Ia: The patients confirming to the eligibility criteria will be assigned to 1 of the 7 dose groups (0.03/0.09/0.3/0.9 mg \~ 0.3/1.5/9.0/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS314 as per the schedule specified in the respective arms. Phase Ib/Ⅱ: Based on the results of Phase Ⅰa, 1 or 2 recommended doses will be selected for Phase Ⅰb. Recommended Phase II Dose (RP2D) will be selected for Phase Ⅱ.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia:Percentage of Participants with Adverse Events (AEs) .Time frame: From Baseline up to approximately 29 months
  2. Phase Ia:Incidence of Dose Limiting Toxicities (DLTs)Time frame: From Baseline up to 4 weeks
  3. Phase Ia:Maximum Tolerated Dose (MTD) of MBS314Time frame: Up to approximately 11 months
  4. Phase Ia:Recommended Phase Ⅱ Dose (RP2D) of MBS314Time frame: Up to approximately 29 months
  5. Phase Ib/Ⅱ :Efficacy: Overall Response Rate (ORR) as Assessed by Independent Review Committee (IRC)Time frame: Up to approximately 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology and Blood Diseases Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.